Quick Takeaways
- PERCEPTIVE ADVISORS LLC filed SCHEDULE 13D/A for Athira Pharma, Inc. Common Stock, $0.0001 par value (ATHA).
- Disclosed ownership: 20%.
- Date of event: 23 Dec 2025.
PERCEPTIVE ADVISORS LLC - 23 Dec 2025 SCHEDULE 13D/A Report for Athira Pharma, Inc. Common Stock, $0.0001 par value (ATHA)
- Filing Manager
- PERCEPTIVE ADVISORS LLC
- Reporting Manager
- Joseph Edelman
- Symbol
- ATHA
- Shares outstanding
- 9,298,756 shares
- Disclosed Ownership
- 1,869,050 shares
- Ownership
- 20%
- Form type
- SCHEDULE 13D/A
- Filing time
- 23 Dec 2025, 17:16:56 UTC
- Date of event
- 23 Dec 2025
- Previous filing
- 22 Dec 2025
- Next filing
- 16 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"PERCEPTIVE ADVISORS LLC disclosed 20% ownership in Athira Pharma, Inc. Common Stock, $0.0001 par value (ATHA) on 23 Dec 2025."
What Changed
- Previous schedule filing date: 22 Dec 2025.
- Current filing was accepted on 23 Dec 2025, 17:16.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 20% | 1,859,322 | 0 | 1,859,322 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | 0001224962 |
| Joseph Edelman | 20% | 1,869,050 | 0 | 1,869,050 | /s/ Joseph Edelman | Joseph Edelman | 0001164426 |
| Perceptive Life Sciences Master Fund, Ltd. | 16% | 1,529,566 | 0 | 1,529,566 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | 0001249675 |
| Perceptive Xontogeny Venture Fund II, LP | 3.5% | 329,756 | 0 | 329,756 | /s/ Joseph Edelman | Joseph Edelman, Managing Partner | 0001851820 |